Nasdaq · CIK 0002022416
SLXN Silexion Therapeutics Corp
Insider trading from SEC Form 4. Last filing Jun 8, 2026. Close $0.22 on Oct 9, 2026, 0% from the 52-week low and -99% from the high.
In brief
Silexion Therapeutics Corp (SLXN) has 18 SEC Form 4 filings on file from 9 insiders, the latest filed on Jun 8, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at SLXN. The newest: Mitchell Shirvan (CSO and CDO) sold $31k of stock on Mar 26, 2026, filed Mar 30, 2026, scored 30 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Silexion Therapeutics Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Mitchell Shirvan CSO and CDO sell | $31k 22,818 shares | -45% | - |
Transactions
Every row filed, 30 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Hadar Mirit Horenshtein CFO and Secretary | AGrant or award Ordinary Shares | +7,500 | $0.00 | $0 | 12,515 | Jun 8, 2026 |
| Jun 4, 2026 | Mitchell Shirvan CSO and CDO | AGrant or award Ordinary Shares | +6,000 | $0.00 | $0 | 8,789 | Jun 8, 2026 |
| Jun 4, 2026 | Ilan Hadar Chairman and CEO | AGrant or award Ordinary Shares | +10,000 | $0.00 | $0 | 16,547 | Jun 8, 2026 |
| Mar 26, 2026 | Mitchell Shirvan CSO and CDO | SOpen-market sale Ordinary Shares | -22,818 | $1.36 | $31k | 27,889 | Mar 30, 2026 |
| Feb 20, 2026 | Shlomo Noy director | AGrant or award Ordinary Sharesindirect: By Guangzhou Sino-Israel Biotech Fund | +9,091 | $0.00 | $0 | 25,399 | Feb 25, 2026 |
| Feb 20, 2026 | Shlomo Noy director | AGrant or award Stock Option (right to buy ordinary shares)derivativeindirect: By Guangzhou Sino-Israel Biotech Fund | +10,685 | $0.00 | $0 | 10,685 | Feb 25, 2026 |
| Feb 20, 2026 | Dror Yosef Abramov director | AGrant or award Ordinary Shares | +9,091 | $0.00 | $0 | 10,180 | Feb 23, 2026 |
| Feb 20, 2026 | Mitchell Shirvan CSO and CDO | AGrant or award Ordinary Shares | +49,726 | $0.00 | $0 | 50,707 | Feb 23, 2026 |
| Feb 20, 2026 | Ruth Alon director | AGrant or award Ordinary Shares | +9,091 | $0.00 | $0 | 10,228 | Feb 23, 2026 |
| Feb 20, 2026 | Ilan Hadar Chairman and CEO | AGrant or award Ordinary Shares | +64,350 | $0.00 | $0 | 65,471 | Feb 23, 2026 |
| Feb 20, 2026 | Hadar Mirit Horenshtein CFO and Secretary | AGrant or award Ordinary Shares | +49,726 | $0.00 | $0 | 50,146 | Feb 23, 2026 |
| Feb 20, 2026 | Avner Lushi director | AGrant or award Ordinary Sharesindirect: By Guangzhou Sino-Israel Biotech Fund | +9,091 | $0.00 | $0 | 25,399 | Feb 23, 2026 |
| Feb 20, 2026 | Amnon Peled director | AGrant or award Ordinary Shares | +7,576 | $0.00 | $0 | 8,237 | Feb 23, 2026 |
| Feb 20, 2026 | Amnon Peled director | AGrant or award Stock Option (right to buy Ordinary Shares)derivative | +8,904 | $0.00 | $0 | 8,904 | Feb 23, 2026 |
| Feb 20, 2026 | Avner Lushi director | AGrant or award Stock Option (right to buy ordinary shares)derivativeindirect: By Guangzhou Sino-Israel Biotech Fund | +10,685 | $0.00 | $0 | 10,685 | Feb 23, 2026 |
| Feb 20, 2026 | Ruth Alon director | AGrant or award Stock Option (right to buy Ordinary Shares)derivative | +10,685 | $0.00 | $0 | 10,685 | Feb 23, 2026 |
| Feb 20, 2026 | Dror Yosef Abramov director | AGrant or award Stock Option (right to buy ordinary shares)derivative | +10,685 | $0.00 | $0 | 10,685 | Feb 23, 2026 |
| Aug 7, 2025 | Ilan Levin director, owner | JOther Ordinary Sharesindirect: By Moringa Sponsor, LP. | -5,550 | $0.00 | $0 | 6,970 | Jan 27, 2026 |
| Sep 15, 2025 | Ilan Levin director, owner | AGrant or award Ordinary Sharesindirect: By Moringa Sponsor, LP. | +450,000 | $4.00 | $1.8M | 456,970 | Jan 27, 2026 |
| Aug 7, 2025 | Ilan Levin director, owner | JOther Warrant (right to buy)derivativeindirect: By Moringa Sponsor, LP. | -935 | $0.00 | $0 | 372 | Jan 27, 2026 |
| Feb 9, 2025 | Dror Yosef Abramov director | AGrant or award Ordinary Shares | +794 | $0.00 | $0 | 794 | Dec 31, 2025 |
| Feb 9, 2025 | Ruth Alon director | AGrant or award Ordinary Shares | +794 | $0.00 | $0 | 794 | Dec 31, 2025 |
| Feb 9, 2025 | Avner Lushi director | AGrant or award Ordinary Sharesindirect: By Guangzhou Sino-Israel Biotech Fund | +1,587 | $0.00 | $0 | 1,587 | Dec 31, 2025 |
| Feb 9, 2025 | Shlomo Noy director | AGrant or award Ordinary Sharesindirect: By Guangzhou Sino-Israel Biotech Fund | +1,587 | $0.00 | $0 | 1,587 | Dec 31, 2025 |
| Feb 9, 2025 | Amnon Peled director | AGrant or award Ordinary Shares | +661 | $0.00 | $0 | 661 | Dec 31, 2025 |
| Feb 9, 2025 | Amnon Peled director | AGrant or award Stock Option (right to buy Ordinary Shares)derivative | +780 | $0.00 | $0 | 780 | Dec 31, 2025 |
| Feb 9, 2025 | Dror Yosef Abramov director | AGrant or award Stock Option (right to buy ordinary shares)derivative | +935 | $0.00 | $0 | 935 | Dec 31, 2025 |
| Feb 9, 2025 | Ruth Alon director | AGrant or award Stock Option (right to buy ordinary shares)derivative | +935 | $0.00 | $0 | 935 | Dec 31, 2025 |
| Feb 9, 2025 | Avner Lushi director | AGrant or award Stock Option (right to buy ordinary shares)derivativeindirect: By Guangzhou Sino-Israel Biotech Fund | +1,872 | $0.00 | $0 | 1,872 | Dec 31, 2025 |
| Feb 9, 2025 | Shlomo Noy director | AGrant or award Stock Option (right to buy ordinary shares)derivativeindirect: By Guangzhou Sino-Israel Biotech Fund | +1,872 | $0.00 | $0 | 1,872 | Dec 31, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Dror Yosef Abramovdirector
- Ruth Alondirector
- Ilan HadarChairman and CEO
- Hadar Mirit HorenshteinCFO and Secretary
- Ilan Levindirector, owner
- Avner Lushidirector
- Shlomo Noydirector
- Amnon Peleddirector
- Mitchell ShirvanCSO and CDO
Questions about SLXN
Answered from the filings on this page, as of the latest one.
Are insiders buying SLXN?
No. In the last 90 days no insider at Silexion Therapeutics Corp bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SLXN on the open market?
Mitchell Shirvan (CSO and CDO) sold $31k of SLXN on Mar 26, 2026 and filed the Form 4 on Mar 30, 2026. InsiderTell scored 30 (weak).
How many insiders file Form 4 at Silexion Therapeutics Corp?
9 people have filed a Form 4 at Silexion Therapeutics Corp, among them Dror Yosef Abramov (director), Ruth Alon (director), Ilan Hadar (Chairman and CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.